Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This clinical study is designed as an open, single group, multi-center, phase 4 clinical
study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to
provide a more reasonable basis for clinical drug programs.